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Introduction 
Thermal  analysis  is  a  technique  in  which  a  physical 
property of a substance and/or its reaction products is 
measured  as  a  function  of  temperature.  Thermal 
analysis can measure weight loss on heating, melting 
points, heat and energy transitions and change in the 
substance  form.  Thermal  analysis  techniques  are 
widely  used  in  the  pharmaceutical  sciences  for  the 
characterization and quality control of drugs, stability, 
drug-excipient  interactions  and  purity  studies  of  raw 
materials and pharmaceutical products.
1-5 
Several  methods  have  been  reported  for  the 
determination  of  the  studied  drugs  including 
chromatographic,
6-9  electrochemical,
10  and  titrimetric 
methods.
11,12  The  use  of  thermal  analysis  for 
antidiabetic  drugs  has  been  very  limited; 
compatibilities of some commonly used pharmaceutical 
excipients  with  glimepiride  and  glibenclamide  have 
been  described.
13,14  Therefore,  the  main  objective  of 
this  study  is  to  investigate  and  compare  the  thermal 
behavior of some antidiabetic drugs such as PTZ, RGZ, 
GBD  and  GMP  using  the  TGA,  DTG  and  DTA 
techniques.  
PTZ is an oral antidiabetic agent used in the treatment 
of type 2 diabetes. After administration, PTZ decreases 
insulin resistance in the periphery and liver resulting in 
increased  insulin  dependent  glucose  disposal  and 
decreased  hepatic  glucose  output.
15,16  RGZ  is  a 
thiazolidinedione  antihyperglycemic  agent  that  works 
by  increasing  insulin  sensitivity  in  target  tissues,  as 
well as decreasing hepatic gluconeogenesis.
17 Oliveira 
et al studied isothermal thermogravimetric studies and 
compatibility between GBD and some pharmaceutical 
excipients  using  thermoanalytical  techniques 
(TGA/DSC).
13 Cides et al studied the thermal behavior, 
compatibility  study  and  decomposition  kinetics  of 
glimepiride  by  using  isothermal  and  non-isothermal 
methods. The activation energy values are 123 and 150 
KJ.mol
- 1 using isothermal method and Onawa method, 
respectively.
14  
GBD and GMP are the potent second generation oral 
sulfonylurea antihyperglycemic agents that widely used 
for the treatment of type 2 diabetes mellitus.
18,19 
 
Materials and methods 
Pioglitazone  hydrochloride  and  rosiglitazone  maleate 
were  obtained  from  Unipharma  and  Apex 
Pharmaceutical  Company,  Egypt,  respectively; 
glibenclamide  and  glimepiride  were  supplied  from 
Aventis Pharmaceutical Company, Egypt. All the used 
drugs have high purity (more than 99%). 
 
Methods 
Thermogravimetric  analysis,  derivative 
thermogravimetry  and  differential  thermal  analysis 
measurements were made by using simultaneous DTA-
TGA  thermal  analyzer  apparatus  (Shimadzu  DTG-
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Purpose:  Thermal  behavior  of  some  antidiabetic  drugs  such  as  pioglitazone 
hydrochloride  (PTZ),  rosiglitazone  maleate  (RGZ),  glibenclamide  (GBD)  and 
glimepiride  (GMP)  has  been  studied.  Methods:  Thermogravimetric  analysis  (TGA), 
derivative thermogravimetry (DTG) and differential thermal analysis (DTA) techniques 
were  used  to  study  the  thermal  behavior  of  the  drugs  under  investigation.  Results: 
Thermal  analysis  technique  was  used  to  obtain  quality  control  parameters  such  as 
melting point 193.13
 °C, 122.42
 °C, 173.75 °C and 208 °C for PTZ, RGZ, GBD and 
GMP,  respectively.  The  values  of  melting  point  of  gave  satisfactory  results  in 
comparison to that obtained by using the official method. Non-isothermal methods were 
employed  to  determine  the  activation  energy  values  of  the  first  stage  of  thermal 
decomposition. Comparison of the activation energy values  suggests the following 
sequence of thermal stability: GMP > GBD > RGZ > PTZ. Conclusion: The results 
obtained  are  useful  for  the  identification  of  these  compounds  and  permitted 
interpretations  concerning  their  thermal  decomposition.  Thermal  stability  of 
pharmaceutical  compounds  can  be  studied  and  compared  by  using  thermal  analysis 
techniques.  
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60H). The weight of samples is ranging from 4 to about 
7  mg,  using  a  platinum  pan.  Measurements  were 
carried out from ambient to 900 °C in dynamic nitrogen 
atmosphere  with  the  flow  rate  of  30  ml  min
-1  and 
heating rate of 10 °C min
-1.  
The activation energies of the used drugs for the first 
stage  of  decomposition  were  obtained  from  TGA 
curves by using Coats-Redren method,
20 and Horowitz-
Metzger method.
21 
 
Coats-Redfern method 
 
The Coats-Redfern method equation can be represented 
as follows: 
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Where  was the heating rate. Since 1- 2RT / E
*1, the 
plot of the left-hand side of equation against 1/T would 
give a straight line. E
* was then calculated from the 
slope  and  the  Arrhenius  constant  (A)  was  obtained 
from the intercept. 
 
Horowitz and Metzger method
  
The Horowitz-Metzger equation can be represented as 
follows:  
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Where Wf was the mass loss at the completion of the 
decomposition  reaction,  W  was  the  mass  loss  up  to 
temperature T, R was the gas constant, Ts was the DTG 
peak temperature and  = T-Ts. A plot of log [log Wf / 
(Wf - W)] against  would give a straight line and E
* 
could be calculated from the slope. 
 
Results and Discussion 
Thermal analysis behavior of PTZ  
The TGA, DTG and DTA curves of PTZ are shown in 
Figure  1.  The  DTG  curve  shows  four  stages  of 
decomposition: At the first stage (145-225.9
 °C); PTZ 
exhibits a weight loss of 9.53% due to the loss of HCl 
molecule. A weight loss of 57.09% observed between 
225.9 °C and 327.73
 °C which may be attributed to the 
loss  of  C10H8NO3S.  Beyond  389.34
  °C,  the  drug 
decomposed in two stages due to the loss of C4H9 at 
389.34-468 °C (weight loss of 14.71%) and the loss of 
C5H3N at 468-551.55 °C (weight loss of 19.47%).  
The DTA curve (Figure 1) shows a small endothermic 
peak at 193.13 °C due to the melting of PTZ which is 
acceptable  to  the  values  of  the  reported  melting 
temperature,
22  and  the  melting  temperature  that 
determined by melting point apparatus (Table 1). An 
exothermic  peak  is  observed  at  270.75  °C 
corresponding  to  the  second  decomposition  stage. 
Another  abroad  endothermic  peak  appears  between 
327.73 °C and 389.34 °C. Two sharp exothermic peaks 
are observed at 444.47 °C and 498.20 °C corresponding 
to  the  third  and  fourth  decomposition  stages  in  the 
DTG  curve,  respectively.  The  results  obtained  from 
TGA,  DTG  and  DTA  indicate  that  PTZ  melts  with 
decomposition.  Thermal  degradation  pattern  of  PTZ 
was shown in Figure 2. 
 
 
Figure 1. Thermal analysis curves (TGA, DTG and DTA) of PTZ. 
 
 
 
Figure 2. Thermal degradation pattern of PTZ. 
 
Thermal analysis behavior of RGZ  
Figure  3  represents  TGA,  DTG  and  DTA  curves  of 
RGZ.  The  TGA  curve  shows  four  stages  of 
decomposition. The DTG curve represents the stages of 
decomposition:  the  first  one  begins  at  150.61  °C  and 
ends at 231.43 °C with a mass loss of 24.50% due to the 
loss  of  C4H4O4  molecule,  the  second  stage  between 
231.43 °C and 317 °C shows weight loss of 24.50% due 
to the loss of C3H2NO2S. RGZ continues to decompose 
in  a  third  stage  (317-481°C)  showing  a  mass  loss  of 
22.39% due to the loss of C7H6O and fourth and last 
stage (481-644.58 °C) with a mass loss of 28.51% which 
may be ascribed to the loss of C8H11N2.   
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Figure 3. Thermal analysis curves (TGA, DTG and DTA) of RGZ. 
 
The DTA curve in Figure 3 shows an endothermic peak 
at 122.42 °C attributed to the melting of the compound 
which agrees to the reported melting temperature,
22 and 
the  melting  temperature  that  determined  by  melting 
point  apparatus.  The  results  were  shown  in  Table  1. 
One  endothermic  peak  is  found  at  192.75
  °C 
corresponding to the first decomposition stage. Broad 
endothermic peak presented from 231.43 °C to 481
 °C 
which  corresponds  to  the  second  and  third  stages  of 
decomposition.  A  very  strong  and  sharp  exothermic 
peak is showed at 556.49
 °C which may be attributed to 
the  last  decomposition  stage.  Thermal  degradation 
pattern  of  RGZ  was  shown  in  Figure  4. 
 
Table 1. The melting points values and the activation energies for the first stage of decomposition of PTZ, RGZ, GBD and GMP. 
Drug 
Melting point (°C)  Activation energy E
* (KJ.mol
- 1) 
DTA Method  Apparatus  Literature
 22  Coats-Redfern method  Horowitz-Metzger method 
PTZ  193.13  194.00  193.00-194.00  77.44  88.19 
RGZ  122.42  123.00  122.00-123.0  102.29  111.72 
GBD  173.75  174.00  172.00-174.00  114.23  126.73 
GMP  208.00  206.00  207.00  125.79  142.62 
 
 
 
Figure 4. Thermal degradation pattern of RGZ. 
 
Thermal analysis behavior of GBD  
The TGA, DTG and DTA curves in Figure 5 show that 
GBD is thermally stable up to 185
 °C. The TGA and 
DTG curves indicate mass losses in three well defined 
stages between 185 °C and 677.53 °C. The mass loss 
28.54% for the first stage (185-286.60 °C) suggests the 
elimination  of  C7H13N2O.  The  second  stage  of 
decomposition  (286.60-392.36
 °C)  involves  a  loss  in 
mass  of  43.13%  which  corresponds  to  the  loss  of 
C10H11NClO2 and  the  third  and  final  stage  (392.36-
677.53  °C)  involves  a  mass  loss  of  28.34%  which 
corresponds to the loss of C6H4SO2.  
 
 
Figure 5. Thermal analysis curves (TGA, DTG and DTA) of GBD. 
 
The  DTA  curve  shows  a  sharp  endothermic  peak  at 
173.75 °C due to the melting of the GBD which is in 
agreement  with  the  values  obtained  from  literature,
22 
and by using melting apparatus (Table 1); this peak is 
followed  by  a  small  and  flattened  endothermic  peak 
from 196  °C  to 286.60
 °C which  corresponds  to  the 
first decomposition stage. At 350.81 °C the DTA curve 
shows a small endothermic peak which corresponds to 
the second decomposition stage and a strong and broad 
exothermic  peak  at  580  °C  which  is  due  to  the  last 
decomposition stage of the drug. Thermal degradation 
pattern of GBD was shown in Figure 6.  
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Figure 6. Thermal degradation pattern of GBD. 
 
Thermal analysis behavior of GMP  
The TGA and DTG curves in Figure 7 show that GMP 
is  thermally  stable  up  to  about  198  °C  and  then 
decomposes in the first stage up to 269.31
 °C with a 
mass  loss  of  31.75%  which  suggests  the  loss  of 
C8H15N2O. GMP continues to decompose from 269.31
 
°C  to  369  °C  in  the  second  stage  of  decomposition 
showing  a  mass  loss  of  39.66%  due  to  the  loss  of 
C10H15N2O2  and  the  third  and  last  stage  in  the 
temperature range of 369-690 °C (28.54%) is ascribed 
to the loss of C6H4SO2.  
 
 
Figure 7.  Thermal  analysis  curves  (TGA,  DTG  and  DTA)  of 
GMP. 
 
The  DTA  curve  of  GMP  (Figure  7)  shows  a  sharp 
endothermic peak at 208 °C that corresponds to melting 
followed by a broad flat exothermic peak between 220 
°C and 480 °C which is corresponding to the first and 
second stages of decomposition of GMP followed by a 
strong  and  broad  exothermic  peak  at  607
  °C 
corresponding  to  the  third  decomposition  stage  of 
GMP. Thermal degradation pattern of GMP was shown 
in Figure 8. 
The previous results show that PTZ, RGZ, GBD and 
GMP start to decompose at 145 °C, 150.61
 °C, 185
 °C 
and  198  °C,  respectively.  These  results  suggest 
increasing thermal stability in the same order. Kinetic 
studies  were  conducted  to  investigate  these  results 
through  calculation  and  comparison of  the  activation 
energies obtained from the first stage of decomposition 
of these drugs. 
 
 
Figure 8. Thermal degradation pattern of GMP. 
 
Determination of activation energies  
For the first order kinetic process, the activation energy 
(E
*)  values  for  the  first  stages  of  decomposition  of 
PTZ, RGZ, GBD and GMP were determined by using 
Coats-Redfern  and  Horowitz-Metzger  methods.  The 
results  are  shown  in  Figure  9  and  Figure  10.  The 
activation  energy  values  of  GMP  are  123  and  150 
KJ.mol
-  1  using  isothermal  method  and  Ozawa's 
method, respectively.
14 These results are in agreement 
with  the  values  obtained  from  Coats-Redfern  and 
Horowitz-Metzger  methods,  and  this  is  an  important 
experimental finding. The results were listed in Table 
1.  It  is  clear  that  the  obtained  values  of  activation 
energies  of  the  used  drugs  are  in  reasonably  good 
agreement.  The  activation  energies  obtained  for  the 
first  stage  of  decomposition  of  these  drugs  show 
different values, suggesting the following sequence of 
thermal stability: GMP > GBD > RGZ > PTZ. 
 
Conclusion  
Thermal analysis methods are widely used in the fields 
of pharmaceutical sciences. The TGA, DTG and DTA 
curves  permitted  interpretations  of  some  antidiabetic 
agents such as PTZ, RGZ, GBD and GMP concerning 
their  thermal  decomposition.  Thermal  stability  of 
pharmaceutical  compounds  can  be  studied  and 
compared  by  using  thermal  analysis  techniques.  The 
results justify the use of DTA as a routine technique for 
the  identification  of  these  drugs  through  the  melting 
point.  Kinetic  results  demonstrated  differences  in 
thermal stability between the four drugs and suggested 
the  following  sequence  of  stability:  GMP  >  GBD  > 
RGZ > PTZ.  
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Figure 9. Coats-Redfern plots of PTZ (a), RGZ (b), GBD (c) and GMP (d), α = W / Wf. 
 
 
 
Figure 10. Horowitz-Metzger plots of PTZ (a), RGZ (b), GBD (c) and GMP (d), α = W / Wf. 
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